NEW YORK, May 28, 2015 /PRNewswire/ -- The controversy surrounding the use of power morcellators (http://www.morcellatorlawsuit2015.com) in hysterectomies and myomectomies (procedures to remove uterine fibroids) continues, as a new report indicates that the FBI is investigating Johnson & Johnson's Ethicon, Inc. unit, which was once the largest manufacturer of the devices. According to the report published by The Wall Street Journal on May 27th, the FBI is trying to determine what the company knew about the potential for power morcellators to spread and upstage undetected uterine cancers.
"As regulatory warnings issued over the past year have made clear, power morcellators are associated with some very significant health risks in cases where undiagnosed cancer cells are present in uterine fibroids. We look forward to learning more about the FBI's findings," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is providing free legal consultations to women who were diagnosed with advanced uterine cancer following surgery with a power morcellator.
Power Morcellators and Cancer
Power morcellators are used in minimally-invasive hysterectomies and myomectomies to shred tissue so that it may be removed through a small abdominal incision. On April 17, 2014, the U.S. Food & Drug Administration (FDA) issued a public alert which discouraged doctors from using the devices in gynecological procedures, due to their potential to spread and upstage undetected uterine cancers. This past November, the agency updated its earlier alert, and warned that the devices should not be used on a majority of women who require these types of surgeries because of this risk. Among other things, the FDA pointed out the difficulty in screening for uterine sarcomas prior to surgery, and noted that a woman's odds of long-term survival are greatly reduced if these malignancies are allowed to spread beyond the uterus.
On July 31, 2014, Ethicon, Inc. announced that it would end sales of power morcellators. At the time, the company said it had decided to do so because the risks and benefits associated with the devices remain uncertain.
Women who allegedly experienced the spread of uterine cancers due to a power morcellator may be entitled to compensation from the manufacturer of the device used in their surgery. To learn more and to arrange for a free review of your potential claim, please visit Bernstein Liebhard LLP's website. To obtain a free legal review, please call (888) 340-4807.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (888) 340-4807. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
SOURCE Bernstein Liebhard LLP